MedTrace Logo

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

NCT04197349 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2020-09-23

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.

Conditions

Interventions

BIOLOGICAL

ALD1910

Single Dose IV infusion

BIOLOGICAL

Sumatriptan

Single dose subcutaneous injection

BIOLOGICAL

ALD1910

Single dose subcutaneous injection

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    collaborator INDUSTRY

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2020-08-19
Completion
2020-08-19

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04197349 on ClinicalTrials.gov